Ignite Creation Date:
2024-05-06 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 12:48 PM
Study NCT ID:
NCT03566485
Status:
TERMINATED
Last Update Posted:
2021-08-11
First Post:
2018-06-11
Brief Title:
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Vanderbilt-Ingram Cancer Center
Organization Data
Organization:
Vanderbilt-Ingram Cancer Center
Class:
OTHER
Study ID:
VICC BRE 17107
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
Ingrid Mayer MD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Vanderbilt-Ingram Cancer Center
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Stand Up To Cancer | OTHER |
| Genentech Inc | INDUSTRY |